Revumenib + Chemotherapy in Newly Diagnosed AML With NPM1 Mutation: Phase 3 REVEAL-ND Study by CheckRare Staff| Published on: Sep 23, 2026

My name is Dr. Joshua Zeidner, and I’m a Professor of Medicine and Chief of Leukemia Research at the University of North Carolina Lineberger Cancer Center. I’m here today to raise awareness around an active global, phase 3, double-blind trial evaluating a combination regimen for participants with a specific type of acute myeloid leukemia or AML. https://checkrare.com/revumenib-chemotherapy-in-newly-diagnosed-aml-with-npm1-mutation-phase-3-reveal-nd-study/